Irritable Bowel Syndrome (IBS) Treatment Global Market Opportunities And Strategies To 2034

This report describes and explains the irritable bowel syndrome (IBS) treatment market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global irritable bowel syndrome (IBS) treatment market reached a value of nearly $6.87 billion in 2024, having grown at a compound annual growth rate (CAGR) of 8.49% since 2019. The market is expected to grow from $6.87 billion in 2024 to $9.88 billion in 2029 at a rate of 7.53%. The market is then expected to grow at a CAGR of 7.28% from 2029 and reach $14.04 billion in 2034.

Growth in the historic period resulted from rise in the prevalence of irritable bowel syndrome (IBS), growth in preventive healthcare, changing dietary patterns and rising personalized medicine and targeted therapies. Factors that negatively affected growth in the historic period were side effects of IBS medications and regulatory hurdles.

Going forward, increasing aging population, increased R&D investments on gut health, growing demand for probiotics and growing adoption of non-pharmacological therapies will drive growth. Factors that could hinder the growth of the irritable bowel syndrome (IBS) treatment market in the future include stigma and lack of awareness high cost of newer therapies and impact of trade war and tariff.

The irritable bowel syndrome (IBS) treatment market is segmented by treatment type into irritable bowel syndrome - constipation-predominant, irritable bowel syndrome - diarrhea-predominant, probiotic drugs and other treatment type. The other treatment type market was the largest segment of the irritable bowel syndrome (IBS) treatment market segmented by treatment type, accounting for 32.26% or $2.21 billion of the total in 2024. Going forward, the irritable bowel syndrome - diarrhea-predominant segment is expected to be the fastest growing segment in the irritable bowel syndrome (IBS) treatment market segmented by treatment type, at a CAGR of 9.14% during 2024-2029.

The irritable bowel syndrome (IBS) treatment market is segmented by indication into IBS with constipation, IBS with diarrhea, IBS with alternating constipation and diarrhea. The IBS with constipation market was the largest segment of the irritable bowel syndrome (IBS) treatment market segmented by indication, accounting for 33.32% or $2.29 billion of the total in 2024. Going forward, the IBS with constipation segment is expected to be the fastest growing segment in the irritable bowel syndrome (IBS) treatment market segmented by indication, at a CAGR of 8.02% during 2024-2029.

The irritable bowel syndrome (IBS) treatment market is segmented by distribution channel into hospital pharmacies, online pharmacies and retail pharmacies. The retail pharmacies market was the largest segment of the irritable bowel syndrome (IBS) treatment market segmented by distribution channel, accounting for 36.03% or $2.47 billion of the total in 2024. Going forward, the online pharmacies segment is expected to be the fastest growing segment in the irritable bowel syndrome (IBS) treatment market segmented by distribution channel, at a CAGR of 11.67% during 2024-2029.

The irritable bowel syndrome (IBS) treatment market is segmented by end-users into hospitals, clinics and homecare settings. The hospitals market was the largest segment of the irritable bowel syndrome (IBS) treatment market segmented by end-users, accounting for 48.27% or $3.32 billion of the total in 2024. Going forward, the homecare settings segment is expected to be the fastest growing segment in the irritable bowel syndrome (IBS) treatment market segmented by end-users, at a CAGR of 8.93% during 2024-2029.

North America was the largest region in the irritable bowel syndrome (IBS) treatment market, accounting for 51.74% or $3.55 billion of the total in 2024. It was followed by Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the irritable bowel syndrome (IBS) treatment market will be Africa and Middle East where growth will be at CAGRs of 13.12% and 11.67% respectively. These will be followed by Asia-Pacific and South America where the markets are expected to grow at CAGRs of 11.03% and 10.31% respectively.

The top opportunities in the irritable bowel syndrome (IBS) treatment market segmented by treatment type will arise in the irritable bowel syndrome - diarrhea-predominant segment, which will gain $1.18 billion of global annual sales by 2029. The top opportunities in the irritable bowel syndrome (IBS) treatment market segmented by indication will arise in the IBS with diarrhea segment, which will gain $1.32 billion of global annual sales by 2029. The top opportunities in the irritable bowel syndrome (IBS) treatment market segmented by distribution channel will arise in the online pharmacies segment, which will gain $1.58 billion of global annual sales by 2029. The top opportunities in the irritable bowel syndrome (IBS) treatment market segmented by end-users will arise in the hospitals segment, which will gain $1.31 billion of global annual sales by 2029. The irritable bowel syndrome (IBS) treatment market size will gain the most in the USA at $917.3 million.

Market-trend-based strategies for the irritable bowel syndrome (IBS) treatment market include focus on launch of microbiome-based IBS therapies, increasing collaborations to develop innovative IBS treatments, personalized nutrition approaches accelerate innovation and digital therapeutics transform IBS management.

Player-adopted strategies in the irritable bowel syndrome (IBS) treatment market include focus on strengthening its operational capabilities through new initiatives.

To take advantage of the opportunities, the analyst recommends the irritable bowel syndrome (IBS) treatment market companies to focus on advancing microbiome-based oral therapies with clinical validation, focus on personalized nutrition therapies for IBS, focus on expanding digital therapeutics for IBS management, focus on diarrhea-predominant IBS treatments, focus on IBS with constipation segment for growth, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use B2B promotions, focus on strategic partnerships to expand IBS treatment options, focus on online pharmacies to capture growth in the IBS treatment market and focus on homecare settings to drive growth.

This product will be delivered within 3-5 business days.